Specifically for AD therapy, our small molecule G9a inhibitor MS1262 showed high brain permeability and stability and much higher potency than existing G9a inhibitors, e.g., > 20-fold more potent than UNC0642 (the older version of G9a inhibitor). Here, EHMT2 is linked to Alzheimer disease.